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Hereditary Hemochromatosis Is Characterized by
a Clinically Definable Arthropathy That
Correlates With Iron Load
G. J. Carroll,1 W. H. Breidahl,2 M. K. Bulsara,3 and J. K. Olynyk4
Objective. To determine the frequency and char-
acter of arthropathy in hereditary hemochromatosis
(HH) and to investigate the relationship between this
arthropathy, nodal interphalangeal osteoarthritis, and
iron load.
Methods. Participants were recruited from the
community by newspaper advertisement and assigned to
diagnostic confidence categories for HH (definite/
probable or possible/unlikely). Arthropathy was deter-
mined by use of a predetermined clinical protocol,
radiographs of the hands of all participants, and radio-
graphs of other joints in which clinical criteria were
met.
Results. An arthropathy considered typical for
HH, involving metacarpophalangeal joints 2–5 and bi-
lateral specified large joints, was observed in 10 of 41
patients with definite or probable HH (24%), all of
whom were homozygous for the C282Y mutation in the
HFE gene, while only 2 of 62 patients with possible/
unlikely HH had such an arthropathy (P  0.0024).
Arthropathy in definite/probable HH was more common
with increasing age and was associated with ferritin
concentrations >1,000 g/liter at the time of diagnosis
(odds ratio 14.0 [95% confidence interval 1.30–150.89],
P  0.03). A trend toward more episodes requiring
phlebotomy was also observed among those with arthro-
pathy, but this was not statistically significant (odds
ratio 1.03 [95% confidence interval 0.99–1.06], P 
0.097). There was no significant association between
arthropathy in definite/probable HH and a history of
intensive physical labor (P  0.12).
Conclusion. An arthropathy consistent with that
commonly attributed to HH was found to occur in 24%
of patients with definite/probable HH. The association
observed between this arthropathy, homozygosity for
C282Y, and serum ferritin concentrations at the time of
diagnosis suggests that iron load is likely to be a major
determinant of arthropathy in HH and to be more
important than occupational factors.
Hereditary hemochromatosis (HH) is a common
inherited metabolic disorder characterized by systemic
iron overload (1–3). It is possible that levels of other
divalent metals could also be increased in HH (4). HH
affects approximately 1 of 200 people and is common in
persons of Northern European origin. Organ damage in
the pancreas, liver, heart, endocrine glands, skin, and
joints has been described in HH. The frequency and
extent of organ damage may be changing with time,
perhaps due to earlier diagnosis and treatment (5). In
persons of Northern European origin, homozygosity for
the C282Y mutation in the HFE gene is present in
90% of patients with unequivocal HH, whereas as
many as 30% of cases in patients of Southern European
origin may be heterozygous or wild-type (WT) for this
mutation (6–8).
Schumacher first described arthropathy as a man-
ifestation of HH in 1964 (9). Since then it has become
accepted that arthropathy is frequent in HH. Arthropa-
thy in HH is usually persistent, refractory to phlebot-
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omy, and structurally irreversible (10–12). It is a major
cause of morbidity, disability, and reduced quality of life
in a substantial proportion of HH patients, regardless of
whether they were treated or untreated (13). A putative
unique and relatively specific form of arthropathy affect-
ing the finger metacarpophalangeal (MCP) joints 2–5 in
particular and/or other joints such as the hip, ankle,
radiocarpal, elbow, shoulder, and knee joints and also
the lumbar spine has been described (14). The frequency
of arthropathy in HH has been reported to be as high as
81% depending considerably on diagnostic criteria and
the method of case ascertainment (15,16). It remains
unknown why arthropathy affects only a subset of pa-
tients with HH, whether this subset can be predicted,
and whether the arthropathy in HH is clinicoradio-
graphically differentiable from other arthropathies, as is
widely believed.
The aim of this study was to investigate the
arthropathy attributed to HH and to specifically deter-
mine 1) the frequency of this and other arthropathies in
HH; 2) the relationship between iron overload and the
development of finger MCP joint arthropathy and other
types of arthropathy in this disorder; 3) whether the
development of the arthropathy is related to the concen-
tration of other commonly measured divalent metals
such as lead, copper, or zinc; and 4) whether the
topography of the arthropathy usually associated with
HH, which we have previously postulated to be analo-
gous to type 2 polyarticular osteoarthritis (OA), can be
distinguished from that of the common form of nodal
interphalangeal (IP) OA, designated type 1 polyarticular
OA (17).
PATIENTS AND METHODS
Study participants. Volunteers age40 years in whom
HH had been diagnosed by a family or specialist physician
were recruited between 2006 and 2009. Recruitment was by
regular newspaper advertisement, which covered the state of
Western Australia. Persons were asked to volunteer for a
medical study. No reference in the advertisement was made to
arthritis, in order to minimize ascertainment bias for arthro-
pathy. The study was approved by the local institutional ethics
and human rights committee.
Participants were evaluated by an experienced rheu-
matologist (GJC) with an interest in OA and hemochromato-
sis. They were interviewed, and historical data were obtained.
Duration of disease was determined from the time of diagno-
sis, not from the time when symptoms, particularly musculo-
skeletal symptoms, first began. Participants were asked to
estimate the number of times they had undergone a phlebot-
omy procedure. A musculoskeletal examination was per-
formed to determine the presence or absence of Heberden’s
nodes and which joints met predetermined range of motion
and other criteria for arthropathy, as shown in Table 1.
Volunteers were excluded from the study if they had
clinical evidence of rheumatoid arthritis (RA), gout, or other
inflammatory arthropathies. All participants were asked to
undergo anteroposterior (AP) radiographic examination of the
hands. Those who fulfilled the criteria for reduced range of
motion in other prespecified joints were asked to undergo
radiographic examination of those joints (AP views and, in the
case of the elbow and ankle joints, lateral views as well). The
number of views was limited in an effort to minimize radiation
exposure. Blood samples were collected for HFE genotyping
and for assays of blood lead and serum copper and zinc.
Diagnostic classification. Whenever possible, the ear-
liest prephlebotomy iron studies, including serum ferritin
concentrations and transferrin saturation, were sourced from
the volunteers themselves, family physicians, and pathology
laboratory databases; however, ascertainment of results was
incomplete (58%). Thus, to determine the likelihood that
volunteers had HH and to classify them in terms of diagnostic
probability, other diagnostic data including HFE genotyping
and phlebotomy history were reviewed in conjunction with the
available iron study findings by an independent physician
experienced in the diagnosis and management of HH (JKO),
who did not have access to any of the other clinical or
radiographic findings or laboratory data. Volunteers were
assigned to the categories of definite, probable, possible, or
unlikely HH and for the purpose of further analysis were
grouped into the categories of definite/probable HH or
possible/unlikely HH.
Occupation. We administered a validated question-
naire used to ascertain occupation and to classify volunteers
according to the duration and intensity of heavy physical labor
(see Appendix A) (18). On the basis of this assessment,
volunteers were assigned a grade from 1 to 4. Higher grades
signify heavier physical labor in terms of extent and duration in
hours per week and years over an occupational lifetime.
Analysis of radiographic findings. Radiographs were
read by an experienced musculoskeletal radiologist (WHB)
who did not have access to any of the clinical or laboratory data
and who was blinded to the diagnostic categories assigned. In
the hands, 32 joints (distal IP [DIP] joints, proximal IP [PIP]
joints, MCP joints, the first carpometacarpal joint, and the
Table 1. Clinical examination criteria for qualifying to undergo
radiography*
Joint Criteria
MCP2–5 Passive flexion 70°†
Radiocarpal Passive extension 50° or passive flexion 40°
Elbow Passive extension deficit of at least 10° or passive
flexion 120°
Hip Passive flexion 100° or passive internal rotation 20°
Knee Passive extension deficit of at least 10° or passive
flexion 120°
Ankle Passive plantar flexion 20°
MTP1 Passive extension 60°
* MCP2–5  metacarpophalangeal joints 2–5; MTP1  first metatar-
sophalangeal joint.
† All patients had hand radiographs.
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scaphotrapezotrapezoidal joint) were assessed and graded for
OA using the Kellgren/Lawrence (K/L) scoring system applied
to OA. This method of grading was deemed to represent the
most appropriate system available, given that no validated
instrument exists for measuring the arthropathy associated
with HH (19,20). We also recorded the presence or absence of
chondrocalcinosis at any site in the hand joints or other imaged
joints or hook-like osteophytes at MCP joints 2–5. Other joints
were graded on the basis of the K/L scoring system where a
valid K/L reference was available, and otherwise on the basis of
the presence or absence of osteophytes and/or sclerosis and the
degree of joint space narrowing. The principles of the K/L
scoring system were applied for those joints for which a valid
K/L reference was unavailable (e.g., ankle joints).
Participants were considered to have the arthropathy
typical for HH in MCP joints 2–5 if the sum of the K/L grades
for the 2 hands was 6. Neither bilateral disease nor any
degree of symmetry was required. There was no requirement
for hook-like osteophytes or chondrocalcinosis. To be consid-
ered to have an arthropathy consistent with HH in the hip,
ankle, radiocarpal, elbow, or knee joints, participants were
required to have at least K/L grade 2 disease bilaterally (those
who had undergone fusion or joint arthroplasty were assigned
a K/L grade of 4). Thus, participants were deemed to have an
arthropathy consistent with HH if they met the predetermined
K/L grade in MCP joints 2–5 and/or if they met prespecified
criteria for at least 1 set of large joints bilaterally. Participants
were also evaluated to determine whether they satisfied crite-
ria for the type 1 polyarticular OA phenotype on the basis of
findings in the hands alone (17). Predefined radiography
criteria were used for this purpose. Participants were deemed
to have type 1 polyarticular OA if the sum of the K/L grades
for DIP joints 2–5 and PIP joints 2–5 in both hands was8 and
the sum of the K/L grades for MCP joints 2–5 was also 2.
HFE genotyping. HFE gene mutations corresponding
to the C282Y and H63D mutations in the gene product were
determined in buffy coat DNA by polymerase chain reaction
amplification using previously described methods, followed by
restriction enzyme cleavage and analysis on a 3% agarose gel.
Participants were assessed for C282Y using the unique Rsa I
digestion site. H63D was determined using the unique Mbo I
digestion site. Subjects were classified as WT homozygotes,
single C282Y/WT or WT/H63D heterozygotes, compound
C282Y/H63D heterozygotes, C282Y homozygotes, and H63D
homozygotes (21).
Assays for blood lead and serum copper and zinc.
Blood lead and serum copper and zinc were measured by
PathWest Laboratories using inductively coupled plasma mass
spectrometry on a Varian 820-MS unit.
Statistical analysis. Data were entered into an Excel
spreadsheet for the purpose of collation and statistical analysis.
Median values and ranges were determined using function
options within Excel. Data were exported to Quickcalcs
GraphPad Statistics for statistical analysis online or evaluated
via Prism offline (GraphPad Software). The significance of
differences was determined by Fisher’s exact test or chi-square
test for categorical variables according to cell numbers, and by
t-test for continuous variables assumed to be normally distrib-
uted. Two-tailed t-tests were performed throughout. Where
data were not normally distributed, nonparametric tests were
used. Univariate and multivariate statistical analyses were
performed using logistic regression models. Odds ratios (ORs)
and 95% confidence intervals (95% CIs) are provided. P values
less than 0.05 were considered significant. No corrections were
made for multiple testing.
RESULTS
One hundred four volunteers attended an initial
interview to receive further information about the study
before consent to participate was requested. One subject
who provided a credible history of RA was excluded.
After being fully informed, no subjects declined to
participate. Thus, 103 subjects were enrolled. Forty-one
participants were assigned to the category of definite or
probable HH, and 62 were assigned to the category of
possible or unlikely HH. These latter participants served
as a control population against whom it was considered
appropriate to compare those with definite or probable
HH on the basis that they had been recruited under
identical circumstances and evaluated in accordance
with the same study protocol before being assigned to a
diagnostic category. The age, sex, and duration of puta-
tive HH for participants in each of these categories are
shown in Table 2. Ninety-six (93%) of those who agreed
to participate in the interview and to undergo an exam-
ination and then radiography actually presented for
radiography, either at or subsequent to the first visit and
after a single written reminder and/or at least 2 tele-
phone reminders. Thirty-eight of the 103 participants
had radiographs of other joints as per protocol. Partici-
pants were well matched with respect to age, sex, disease
duration, hand dominance, and occupational grade.
There was a marked predominance of C282Y
homozygous participants in the definite/probable HH
category (85%) (Table 3), as would be expected in
classic HH, compared with a majority of heterozygous
Table 2. Characteristics of the study participants*
Subjects with
definite/probable
HH (n  41)
Subjects with
possible/unlikely
HH (n  62)
Male, no. (%) 18 (44) 25 (40)
Age, median (range) years 58 (43–77) 60 (41–83)
Duration of HH, median
(range) years
7 (1–20) 4 (1–30)
Right hand dominant, % 94 86
Occupational category (1–4),
mean  SD
2.0  1.1 2.4 1.06
Had undergone
hysterectomy, no. (%)
5 (22) 15 (41)
* There were no significant differences between the groups. HH 
hereditary hemochromatosis.
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(compound and single), WT homozygous, and H63D
homozygous participants collectively in the possible/
unlikely HH control group (69%).
Table 4 provides the frequency of reported ar-
thralgia and the clinical and radiographic features of
arthropathy for definite/probable HH and for possible/
unlikely HH. Either arthropathy of MCP joints 2–5 or
bilateral prespecified large joint arthropathy was ob-
served in 10 of the 41 subjects (24%) with definite/
probable HH. The frequency of such arthropathy among
persons age 60 years was still higher at 36% (8 of 22
subjects). Our results are similar to the findings reported
by Valenti et al (22) in a survey of well-documented
Italian patients with HH in a tertiary hospital setting.
Those investigators observed MCP arthropathy typical
for HH in 36% of patients and at least unilateral hip
arthropathy in 35% of patients. In our study, arthro-
pathy of MCP joints 2–5 alone, bilateral hip arthropathy,
and bilateral prespecified large joint arthropathy as a
whole were observed significantly more frequently in the
definite/probable HH group. Bilateral ankle arthropathy
alone was not found to be significantly more frequent in
definite/probable HH (n  2).
Hook-like osteophytes, which are a well-
recognized feature of the hand arthropathy in HH, were
also found significantly more often in the definite/
probable HH group. Moreover, all subjects with hook-
like osteophytes were homozygous for the C282Y mu-
tation in the HFE gene. Arthralgia was just as frequent
in the subjects with definite/probable HH as it was in the
controls. Likewise, Heberden’s nodes and the hand
equivalent of the type 1 polyarticular OA phenotype
were found with very similar frequency in these 2
groups. Bilateral OA of the first MTP joint was not
Table 3. HFE genotype according to diagnostic category*
HFE
genotype
Subjects with
definite/probable
HH (n  41)
Subjects with
possible/unlikely
HH (n  62)
C282Y/C282Y 35 (85) 19 (31)
C282Y/H63D 4 (10) 17 (27)
C282Y/WT 0 (0) 10 (16)
WT/WT 2 (5) 5 (8)
WT/H63D 0 (0) 10 (16)
H63D/H63D 0 (0) 1 (2)
* Values are the number (%) of subjects. HH hereditary hemochro-
matosis; WT  wild-type.
Table 4. Clinical and radiographic findings in the study participants*
Subjects with
definite/probable
HH (n  41)
Subjects with
possible/unlikely
HH (n  62) P†
Reported arthralgia 32 (78) 49 (79) 1.00
Heberden’s nodes 17 (41) 24 (39) 0.84
At least 1 clinically abnormal joint 21 (51) 16 (26) 0.0202
Hook-like osteophytes‡ 7 (17) 1 (2) 0.0207
Chondrocalcinosis 2 (5) 2 (3) 1.0000
Arthropathy of MCP2–5 based on sum of the K/L grades 6 6 (15) 1 (2) 0.0467
Bilateral hip arthropathy based on K/L grade 2§ 4 (10) 1 (2) 0.0144
Bilateral ankle arthropathy based on K/L equivalent grade 2¶ 2 (5) 0 (0) 0.1561
Bilateral prespecified large joint arthropathy 7 (17) 2 (3) 0.0282
STT joint arthropathy based on the sum of the K/L grades 2 for the left and right joints 11 (27) 13 (21) 0.6345
Bilateral arthropathy of MTP1 based on K/L grade 2 4 (10) 4 (6) 0.7099
Arthropathy of either MCP2–5 or bilateral prespecified large joints (radiocarpal, elbow,
hip, knee, ankle)#
10 (24) 2 (3) 0.0024
Hand equivalent of type 1 polyarticular OA phenotype 7 (17)** 13 (21)** 0.80
* Values are the number (%) of subjects. STT  scaphotrapezotrapezoidal; MTP1  first metatarsophalangeal joint.
† P values less than 0.05 were considered significant.
‡ All 7 subjects with definite/probable hereditary hemochromatosis (HH) and hook-like osteophytes had the C282Y/C282Y HFE genotype. The 1
subject with possible/unlikely HH and hook-like osteophytes had the H63D/H63D HFE genotype.
§ No subject had unilateral hip arthropathy.
¶ The principles of the Kellgren/Lawrence (K/L) scoring system were applied for measuring ankle arthropathy since a valid K/L reference was
unavailable. Only 1 subject (classified as having possible HH) had unilateral ankle arthropathy.
# Two subjects had grade 3 elbow arthropathy, 1 (classified as having probable HH) with unilateral arthropathy and 1 (classified as having possible
HH) with bilateral arthropathy. No subjects met the predetermined clinical criteria for knee osteoarthritis (OA). No subjects were found to have
OA of K/L grade 2 in the radiocarpal joints. All 10 subjects with definite/probable HH and arthropathy of either metacarpophalangeal joints 2–5
(MCP2–5) or bilateral prespecified large joints had the C282Y/C282Y HFE genotype. Of the 2 subjects with possible/unlikely HH and arthropathy
of either MCP2–5 or bilateral prespecified large joints, 1 had the C282Y/wild-type HFE genotype and 1 had the C282Y/H63D HFE genotype.
** Four female subjects and 3 male subjects with definite/probable HH and 10 female subjects and 3 male subjects with possible/unlikely HH.
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found to be significantly more frequent in the definite/
probable HH group. No differences were observed in
mean occupational grade between those with definite/
probable HH who had arthropathy of MCP joints 2–5
and bilateral prespecified large joint arthropathy and
those with possible/unlikely HH who had no arthropathy
of MCP joints 2–5 and no bilateral prespecified large
joint arthropathy (2.5 and 2.4, respectively; P  0.79).
Table 5 provides selected clinical features and
measures of iron load in participants with definite/
probable HH who had either arthropathy of MCP joints
2–5 or bilateral prespecified large joint arthropathy and
compares them with those in participants with definite/
probable HH who had neither arthropathy of MCP
joints 2–5 nor bilateral prespecified large joint arthro-
pathy. In participants with definite/probable HH, arthro-
pathy was found to be associated with age (OR 1.11
[95% CI 1.02–1.31], P  0.014) but not with disease
duration. A univariate analysis showed that ferritin
concentrations in excess of 1,000 g/liter at the time of
diagnosis were strongly associated with the development
of arthropathy (OR 14.0 [95% CI 1.30–150.89], P 
0.03). Insufficient data were available for a more robust
multivariate analysis to be conclusive. However, after
adjusting for age, participants with ferritin concentra-
tions 1,000 g/liter at the time of diagnosis were still
found to be at significantly greater risk of arthropathy
(OR 16.98 [95% CI 1.09–263.92]). It should be noted
that serum ferritin concentrations at the time of diagno-
sis were available for the purpose of this study in only 27
of the 41 participants with definite or probable HH;
likewise, the number of phlebotomies performed was
available for only 39 of these 41 participants. A trend
toward more episodes requiring phlebotomy was also
observed among those with arthropathy, but this was not
statistically significant (OR 1.03 [95% CI 0.99–1.06],
P  0.097).
A positive family history of HH was observed
more often in participants with definite/probable HH
who had arthropathy (56%) than in those who did not
(32%), but the difference was not statistically significant
(P  0.26). All 10 of the participants with definite/
probable HH who had arthropathy were homozygous
for C282Y (OR 3.03); however, this was not statistically
significant (P  0.328). A trend toward higher occupa-
tional grades (more physical labor) was observed in
those with arthropathy, but this difference also was not
statistically significant (P  0.12).
Concentrations of other divalent metals including
blood lead and serum copper and zinc were measured in
all participants. Those with definite/probable HH and
arthropathy had higher blood lead concentrations than
those with definite/probable HH without arthropathy
(mean  SD 3.5  1.1 g/100 ml versus 2.4  1.2 g/
100 ml; P  0.0272); however, the importance of this
observation is uncertain, since a smaller and statistically
Table 5. Characteristics of the participants with definite or probable HH with and without arthropathy*
Arthropathy of MCP2–5
or bilateral prespecified
large joint arthropathy
(n  10)
Neither MCP2–5 arthropathy
nor bilateral prespecified
large joint arthropathy
(n  31) P†
Univariate analysis
(logistic regression
model)
OR (95% CI) P
Age, median (range) years 68 (49–77) 55 (41–75) 0.029‡ 1.11 (1.02–1.31) 0.014
Male/female 6/4 17/14 0.78 1.24 (0.29–5.26) 0.775
HFE genotype 10 C282Y/C282Y 25 C282Y/C282Y, 4 C282Y/
H63D, 2 WT/WT
0.58 3.03§ 0.328
Duration of HH, median (range) years 13 (1–20) 7 (1–17) 0.21 1.11 (0.98–1.27) 0.106
Family history of HH in at least 1 sibling,
no./total no. (%)
5/9 (56) 10/31 (32) 0.255 – –
High iron load (ferritin 1,000 g/liter at
diagnosis), no./total no.
5/6 5/19 0.023‡ 14.0 (1.30–150.89) 0.03
Phlebotomies required because of iron load,
median (range) [no. of patients]
56 (30–180) [7] 38 (0–88) [30] 0.136‡ 1.03 (0.99–1.06) 0.097
Occupational grade, mean  SD¶ 2.50 1.30 1.87  0.97 0.115 – –
Occupational grade, no. with 3 or 4/no. with 1 or 2 6/4 8/21 0.124 – –
* Data for some variables could not be traced and were therefore incomplete (e.g., serum ferritin at diagnosis, number of phlebotomies).
HH  hereditary hemochromatosis; MCP2–5  metacarpophalangeal joints 2–5; OR  odds ratio; WT  wild-type.
† P values less than 0.05 were considered significant.
‡ By nonparametric statistical test (Kolmogorov-Smirnov test).
§ Upper limit of 95% confidence interval (95% CI) could not be estimated; lower limit was 0.39.
¶ Higher grade indicates more physical labor.
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nonsignificant difference in lead concentration was ob-
served when those with definite/probableHHand arthro-
pathy were compared with those with possible/unlikely
HH, in whom arthropathy was uncommon (mean  SD
3.5  1.1 g/100 ml and 3.0  1.6 g/100 ml, respec-
tively; P  0.3592). In no participant was the blood lead
concentration above the upper limit of the clinically
accepted normal range. Serum copper concentrations
were found to be lower in those with definite/probable
HH and arthropathy than in those with possible/unlikely
HH (mean  SD 15.0  2.1 moles/liter versus 17.2 
3.4 moles/liter; P  0.0391).
DISCUSSION
An arthropathy involving either the finger MCP
joints or bilateral prespecified large joints and deter-
mined a priori to be characteristic of HH was found to
complicate definite or probable HH, confirming and
extending previous observations (9–11,14,22). In clinical
practice and in our study, this arthropathy can be readily
distinguished from the type 1 polyarticular OA pheno-
type. The latter, which is common in the same age
group, occurred just as often in definite or probable HH
as in possible or unlikely HH. In contrast, arthropathy of
MCP joints 2–5 or bilateral prespecified large joint
arthropathy was found to occur in 24% of participants
with definite/probable HH, but in only 3% of those with
possible/unlikely HH. Arthropathy was associated with
age (OR 1.11) and was thus more common late in the
course of the disease. It occurred mostly in the absence
of chondrocalcinosis, which in our study was an infre-
quent disease manifestation. Furthermore, serum fer-
ritin concentrations 1,000 g/liter at the time of diag-
nosis were found to be a strong predictor of arthropathy
independent of age (OR 14.0).
This study of arthropathy in HH has a number of
strengths and weaknesses. Perhaps its chief strength is
that unlike previous studies, our study was community
based. In contrast, previously reported studies have been
retrospective observational series and have assessed
patients with idiopathic hemochromatosis or HH who
were mainly in tertiary referral centers where more
severe cases were likely to have been concentrated and
where arthropathy may have been overrepresented. Our
study more likely reflects the wider spectrum of HH
disease severity in the population. Furthermore, ascer-
tainment bias with respect to arthritis was minimized by
the nondisclosure of an arthritis focus in the newspaper
advertising used to recruit participants. Assessment ac-
cording to a predetermined clinical protocol together
with the requirement for hand radiographs in all partic-
ipants and other joint radiographs where predetermined
clinical criteria were satisfied added rigor to the study.
The application of a recognized grading system for
radiographic findings and the use of “blinded assess-
ment” (radiographs graded without knowledge of the
clinical classification of participants) represent addi-
tional strengths. Another important aspect of the study
is the availability of an internal control group. This was
possible because a substantial number of volunteers for
the study did not meet criteria for assignment to the
category of definite/probable HH and were assigned to
the category of possible/unlikely HH.
The study also has a number of weaknesses.
Because participants were not referred by physicians and
since they usually did not have accessible hospital
records, diagnostic laboratory data were limited. Fur-
thermore, some participants had putative HH of very
long duration and/or had changed their family physician
since diagnosis, which hindered the tracing of initial
laboratory results. For example, the iron studies that
supported the initial diagnosis could not be traced in
40% of the study population. The relatively small
number of patients with verifiable arthropathy limited
the statistical power of the study.
The main findings in our study relate to the
confirmation of an arthropathy consistent with HH
(arthropathy of MCP joints 2–5 or bilateral prespecified
large joint arthropathy), the distinction of this arthro-
pathy from that conforming to nodal generalized OA
(classified here as type 1 polyarticular OA in the hand),
and the identification of a serum ferritin concentration
1,000 g/liter at the time of diagnosis as an important
predictor of arthropathy in HH. Occupational factors,
and particularly long-term heavy physical labor, could
not be shown to contribute to the development of
arthropathy.
Other investigators have reported a strong rela-
tionship between iron load in arthropathy in HH in
general and MCP arthropathy in the hand in particular
(22). It is not clear to what extent genetic factors account
for susceptibility to arthropathy in HH. In our study and
in those by others, arthropathy was strongly associated
with homozygosity for C282Y (all 10 participants with
definite/probable HH who met criteria for arthropathy
consistent with HH were C282Y homozygous) (22). It is
possible that arthritis susceptibility genes are coinher-
ited with HFE mutations. However, it is worth noting
that a very similar form of MCP arthropathy has been
reported in juvenile hemochromatosis in which iron
overload occurs on a different genetic background (23).
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Thus, whatever the mechanism, iron load may be the
crucial determinant, and genetic factors may act to
facilitate or hinder the development of arthropathy
and/or the number and the topography of the joints
affected.
Our results are consistent with those of Bulaj et al
(24), who determined the frequency of MCP joint
arthropathy by radiographic assessment (criteria not
defined) in clinically unselected C282Y homozygous
relatives of probands with HH with and without iron
overload. In our study, 3 of 23 men with definite or
probable HH had finger MCP arthropathy (mainly of
MCP joints 2 and 3) (13%) as did 3 of 19 women (16%).
Bulaj et al reported MCP arthropathy consistent with
HH in 17 of 113 male C282Y homozygous relatives with
iron overload (15%) and in 3 of 69 C282Y homozygous
female relatives with iron overload (4%). Our results are
also similar to those of Schumacher (9), who in his initial
description of arthropathy in hemochromatosis reported
that 5 of 23 males (22%) with idiopathic hemochroma-
tosis had a clinically recognizable peripheral arthritis.
The observation that the arthropathy of HH is
found more often in older patients is consistent with the
possibility that an iron deposition threshold may need to
be reached in order for osteochondral damage to occur
(15,16). It is noteworthy that regular phlebotomy and
thus systemic iron depletion in HH patients with arthro-
pathy is seldom helpful for symptom relief (10–12).
Moreover, iron depletion seems not to retard or reverse
the progressive deterioration in joint structure. It is
possible that in HH, iron may become sequestered or
trapped in joint tissues and no longer available for
removal by phlebotomy, unlike in other tissues/organs
such as the liver. The detection of appreciable hemosid-
erin in synovium from HH patients with arthropathy at
the time of joint surgery, but not in synovium from
patients with OA or RA, supports this proposition (25).
Moreover, the consistent finding of hemosiderin in the
synovium of HH patients after extensive phlebotomy
attests to the persistence of iron in the synovial tissue
despite systemic iron depletion. Taken together, these
observations suggest that iron may progressively accu-
mulate in joint tissues where it persists despite regular
phlebotomy and eventually produces irreversible osteo-
chondral damage accompanied by intractable symptoms.
One of us (GJC) previously obtained a specimen
of synovial fluid (SF) from a pathologic joint in a patient
with proven C282Y homozygous HH who had a severe
form of arthropathy typical for HH. SF was collected
from the patient’s left hip joint immediately after the
joint was opened in preparation for a hip arthroplasty. In
this patient, the SF ferritin concentration was found to
be 5,374 g/liter, while at the same time the serum
ferritin concentration was 1,366 g/liter. Further studies
comparing SF ferritin with serum ferritin in patients with
HH and in other arthropathies may help to clarify
whether, despite phlebotomy, the SF ferritin level re-
mains high in treated HH patients. The observation that
concentrations of ferritin are higher in SF from OA
patients who have HFE gene mutations than in SF from
WT OA patients is also consistent with the possibility
that localized iron deposition may contribute, although
to a lesser extent, to joint damage in idiopathic OA (26).
Ferritin has recently been shown to act as a proinflam-
matory cytokine and could contribute directly to joint
injury (27). Importantly, in hepatic stellate cells, at
nanomolar concentrations similar to those observed in
the SF of the patient described above, ferritin was found
to be a potent and rapid inducer of interleukin-1 (IL-1)
gene expression (27). IL-1 is strongly implicated in
cartilage and bone resorption (28–32). Accordingly, it
may be an important mediator of osteochondral damage
in the joints of patients with HH.
Intriguingly, a clinically and radiographically sim-
ilar arthropathy, closely resembling arthropathy of MCP
joints 2–5 with or without similar large joint arthropathy,
occurs commonly in a subset of patients with polyartic-
ular OA in whom HH has been excluded (17). It has
long been recognized that MCP arthropathy closely
resembling but not due to HH occurs commonly in the
hand, and more recently several teams of investigators
have reported that hand joint arthropathy and particu-
larly MCP joint arthropathy are associated with muta-
tions in the HFE gene (33–35). In the more extended
phenotype designated type 2 polyarticular OA, 75% of
patients who met strict clinicoradiographic criteria for
this classification were found to have one or more HFE
gene mutations, most commonly the H63D mutation
(17). Higher serum ferritin concentrations were also
found in these patients. It is possible that in patients with
idiopathic polyarticular OA in whom the arthropathy
closely resembles that typical for HH (putative type 2
polyarticular OA) and in whom HFE gene mutations are
common, a less severe degree of articular iron deposi-
tion may contribute to joint damage.
In conclusion, an arthropathy consistent with that
reported commonly in HH was found to occur in
approximately one-fourth of patients with definite or
probable HH recruited from the community. The asso-
ciation observed between this arthropathy, homozygos-
ity for C282Y, and iron load as reflected by serum
ferritin concentrations 1,000 g/liter at the time of
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diagnosis suggests that iron load is likely to be a major
determinant of arthropathy in HH and to be more
important than occupational factors.
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APPENDIX A: OCCUPATIONAL HISTORY QUESTIONNAIRE
The following occupational history questionnaire was used to ascertain and identify participants according to occupation and intensity of
hard physical labor during an occupational lifetime.
1. During the years that you have been in paid employment what has been your main occupation?
Answer:
2. Which of these 4 categories best describes what you have done in the course of your main occupation?
a) mainly sedentary work
b) job includes mainly standing and walking or light handling of materials without heavy physical loading
c) in addition to standing and walking the job includes (included) frequent lifting and carrying
d) hard manual work
3. In the course of your working life were you involved in any occupation that required hard manual work for more than
5 years?
Yes 
No 
If yes, please complete the following:
For up to 5 hours per week 
For 5 to 10 hours per week 
For more than 10 hours per week 
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